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Background: Intimal sarcoma (InS) is an exceedingly rare neoplasm with an unfavourable 
prognosis, for which new potentially active treatments are under development. This is to 
report on the activity of anthracycline-based regimens, gemcitabine-based regimens and 
pazopanib in patients with InS. 
Methods. Seventeen sarcoma reference centres in Europe, US and Japan contributed 
data to this retrospective analysis. Patients with MDM2-positive InS treated with 
anthracycline-based regimens, gemcitabine-based regimens or pazopanib between 
October 2001 and January 2018 were selected. Local pathological review was performed 
to confirm diagnosis. Response was assessed by RECIST1.1. Recurrence-free survival 
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Results: Seventy-two patients were included (66 anthracycline-based regimens; 26 
gemcitabine-based regimens; 12 pazopanib). In the anthracycline-based group, 24 (36%) 
patients were treated for localized disease, 42 (64%) patients for advanced disease. Real-
world overall response rate (rwORR) was 38%. For patients with localized disease, the 
median RFS was 14.6 months. For patients with advanced disease, the median PFS was 
7.7 months. No anthracycline-related cardiac toxicity was reported in patients with cardiac 
InS (n=26). For gemcitabine and pazopanib the rwORR was 8% and the median PFS 3.2 
and 3.7 months, respectively,
Conclusions: This retrospective series shows activity of anthracycline-based regimens in 
InS. Of note, anthracyclines were used in patients with cardiac InS, with no significant 
cardiac toxicity. The prognosis in patients with InS remains poor and new active drugs and 
treatment strategies are needed. 
Key words. Intimal sarcoma, systemic therapies, anthracycline, gemcitabine, pazopanib, 
MDM2.
Introduction
Intimal sarcoma (InS) is an extremely rare, mesenchymal neoplasm originating from large 
blood vessels and from the heart, being one of the most common primary cardiac 
histologies1,2. Regarded as a high-grade tumour, it is marked by MDM2 nuclear 
overexpression, and amplification of the 12q12-15 region (containing CDK4 and MDM2)3. 
These molecular features suggest that this pathway might play a relevant role in tumour 
pathogenesis and that MDM2 inhibition might represent a potential treatment strategy in 
this disease. The outcome for InS patients is poor, with a reported median overall survival 
(mOS) in the range of 8-13 months4,5. 
Retrospective data on the activity of systemic therapies in InS are limited and no 
prospective studies have been conducted 4,6-10.  This lack of knowledge is increasingly 
important today, as new potentially active treatments are emerging. 
This academic, international, collaborative effort, including 17 referral sarcoma centres in 
the EU, US and Japan, within the World Sarcoma Network initiative, aims to report on the 
activity of medical agents available for treatment of soft tissue sarcomas (STS), i.e. 
anthracycline-based regimens, gemcitabine-based regimens, and pazopanib, in adult 
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Patient population
We sought data regarding adult patients with InS, treated with anthracycline-based 
regimens, gemcitabine-based regimens or pazopanib, between October 2001 and January 
2018. Both patients with localized disease treated with curative intent and with advanced 
disease (locally advanced not eligible for complete surgical resection, or definitive RT, or 
metastatic) were included. A written informed consent to the treatment was obtained as 
required by local regulation. Approval by the Institutional Review Board of each 
participating institution was required.
Study design and data collection
Data were extracted from clinical databases and confirmed through a review of patient 
records (Table 1 reports contributions). Only cases in which diagnosis of MDM2-positive 
InS was histologically reviewed and confirmed by a sarcoma pathologist at the respective 
institution were included. MDM2 status was determined by immunohistochemistry and/or 
molecular testing. Response was assessed by RECIST 1.111. 
Statistical analyses
Descriptive statistics and frequency tabulation were used to summarize patient and tumor 
characteristics. Real-world overall response rate (rwORR) was defined as the proportion of 
patients who achieved complete response (CR) or partial response (PR) by RECIST.
 Recurrence-free survival (RFS), progression-free survival (PFS) and OS were estimated 
using the Kaplan-Meier method. Survival distributions were compared using the log-rank 
test. In patients receiving anthracycline-based regimens and treated for localized disease 
with curative intent, RFS was calculated as the interval from primary treatment to the date 
of the first evidence of recurrence, death for any reason or the last follow-up. PFS was 
calculated as the interval from the start of the medical treatment to the date of progressive 
disease (PD), death for any reason or the last follow-up. OS was calculated as the interval 
from the start of treatment to the time of death for any reason or the last follow-up. A two-
sided p<0.05 was considered statistically significant. Statistical analyses were carried out 
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Ninety-eight adult patients were retrospectively identified and 72 included after histological 
review (anthracycline-group: 66; gemcitabine-group: 26; pazopanib-group: 12). Twenty-six 
patients received more than one treatment. The median follow-up was 36.3 months. Table 
2 summarizes population characteristics. 
Treatment response and outcome
Table 3 reports treatment details.
 Anthracycline-based regimens
Sixty-six patients were included, 50 were evaluable for response. Sixteen patients 
underwent surgery before chemotherapy, and therefore were not evaluable for response 
(however, they were included in the calculation of RFS). Anthracyclines were used as a 
first-line treatment in 59 (89%) patients, as a second-line treatment in 6 (9%) and as a 
further line in 1 (2%). Twenty (30%) patients received anthracyclines as single agent, 39 
(59%) as a combination with ifosfamide, and 7 (11%) as a combination with a different 
compound. Sixty-four patients (97%) completed the treatment at the time of the analysis: 
15 (23%) for progressive disease, 9 (13%) for toxicity, 25 (38%) for having received a 
maximum cumulative dose and 17 (26%) for other reasons. 
Best RECIST response was 2 (4%) CR, 17 (34%) PR, 24 (48%) stable disease (SD), and 
7 (14%) PD. The rwORR was 38%.  
For patients with localized disease treated with curative intent (n=24), the median RFS and 
mOS were 14.6 (IQR: 9.1-35.7) and 50.8 (IQR: 33.8-N.E.) months, respectively. Five 
patients were alive and disease free at >2 years: 2 patients had chemotherapy and 
exclusive radiation therapy; 1 patient had chemotherapy, surgery and radiation therapy; 2 
patients had chemotherapy and surgery. Table 3 describes treatment details.
For patients with advanced disease (n=42), the median PFS (mPFS) and mOS were 7.7 
(IQR: 4.1-16.9) and 21.8 (IQR: 10.3-38) months, respectively. The median PFS in 
responding patients was 9 months, compared to 5 months in non-responding patients 
(P=0.02). Two patients are alive and disease free at more than 2 years (one patient 
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therapy on the primary; one patient metastatic to the lung underwent lung 
metastasectomy, chemotherapy and exclusive radiation therapy on the primary).
No cardiac toxicity was observed in patients with cardiac InS (n=26). Figure 1 shows 
Kaplan-Meier curves.
 Gemcitabine-based regimens
Twenty-six patients were included, 25 evaluable for response (one had surgery prior to 
chemotherapy). Gemcitabine-based regimens were used as a first-line treatment in 6 
(23%) patients and as a second-line treatment in 20 (77%). Seven (27%) patients received 
gemcitabine as single agent, 16 (62%) as a combination with docetaxel, and 3 (11%) as a 
combination with a different compound. All patients completed the treatment at the time of 
the analysis: 20 (77%) for progressive disease, 2 (8%) for toxicity and 4 (15%) for other 
reasons.
Best RECIST response with gemcitabine-based regimens was 2 (8%) PR, 7 (28%) SD and 
16 (64%) PD. rwORR was 8%.  
For patients with advanced disease (n=24), the mPFS and mOS were 3.2 (IQR: 2.1-7.1) 
and 13.1 (IQR: 7.6-16.5) months, respectively.
 Pazopanib
Twelve metastatic patients were included, all evaluable for response. Pazopanib was used 
as a first-line treatment in 1 (8%) patient, as a second-line treatment in 3 (25%) and as a 
further line in 8 (67%). All patients completed the treatment at the time of the analysis: 11 
(92%) for progressive disease and 1 (8%) for toxicity.
Best RECIST response with pazopanib was 1 (8%) PR, 4 (34%) SD, and 7 (58%) PD. The 
rwORR was 8%. The mPFS and mOS were 3.7 (IQR: 2.6-4.6) and 12.1 (IQR: 4.1-18.9) 
months, respectively.
Discussion
This academic, multi-institutional, international, retrospective study collected the largest 
series currently available of adult patients affected by MDM2-positive InS treated with 
systemic therapy. Seventy-two patients (66, anthracycline-group; 26, gemcitabine-group; 
12, pazopanib-group) were included. Anthracycline-based regimens showed a degree of 
activity towards the higher limits observed in STS (rwORR 38%, mPFS 7.7 months), 
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3.2 and 3.7 months, respectively), though they were mainly used in advanced disease and 
further lines.
InS is extremely rare, mostly diagnosed in adult patients and often arising from critical 
anatomic sites, thus being an often life-threatening tumour even when localized. In this 
series, pulmonary artery was the most common primary site (56%), followed by heart 
(36%). Notably, 23/26 (88%) cardiac InS originated from the left atrium. Pathology review 
in sarcoma reference centres led to the exclusion of approximately 25% of the cases 
diagnosed in the community. 
The previous data available are confined to case reports and small retrospective series, 
not always reporting MDM2 status, and suggest a poor activity of chemotherapy in InS, 
with few anecdotal responses observed4,6,8. In our series, including only confirmed MDM2-
positive cases, InS showed sensitivity to anthracycline-based regimens, possibly greater 
than expected in other STS and to what has been reported previously by Van Dievel and 
Penel, who observed no responses over 5 InS patients each4,8,12. Given InS challenging 
sites of origin, tumor shrinkage may be crucial both in the localized and advanced stages, 
as it may facilitate local treatment (surgery and/or radiation therapy), control symptoms 
and improve patient’s quality of life. Unfortunately, mPFS for advanced disease was only 
7.7 months. This unfavourable prognosis is consistent with previous findings4,8,13. 
Prognosis was also unsatisfactory in patients with localized disease, treated with 
anthracycline-based regimens plus an intended definitive local treatment, with a14.6-
month mRFS. However, it is worth noting that around 25% of patients with localized 
disease are expected to be alive and disease-free at >2 years. This suggest a possible 
role for (neo)adjuvant treatment in InS patients, although this series did not establish a 
comparison estimate of RFS for patients without chemotherapy, and a randomized study 
would be exceedingly difficult to accrue for this rare sarcoma subtype.
With a median follow up of 36 months, no cardiac complications were observed following 
treatment with anthracyclines in this series. No data are available on long-term toxicity 
and, due to the retrospective nature of the study, asymptomatic cardiac toxicity could have 
been missed. However, though expected cardiac risk must be assessed individually, this 
observation in a significant number of patients may contribute to clinical decision-making. 
In contrast to angiosarcoma, another vascular sarcoma potentially arising from the heart, a 
low rwORR (8%) and a limited m-PFS (3.2 months) were observed with gemcitabine-
based chemotherapy14. Similarly, the activity of pazopanib, previously suggested by Kollar 
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PFS 3.7 months)6,7. Of note, if anthracyclines were mostly used upfront, gemcitabine and 
pazopanib were mainly used as further lines.
In conclusion, our results show that anthracycline-based regimens are a potentially 
effective medical option in InS. The value of gemcitabine and pazopanib was limited 
(though possibly exploitable as further-line therapy or in patients unfit for anthracyclines). 
The prognosis of InS patients remains poor, and new medical options are needed both in 
the localized and in the metastatic stages. MDM2 inhibitors are emerging as a promising 
venue in InS, requiring prospective studies. This series may be used as a benchmark for 
such future trials. 
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Table 1. Intimal sarcoma cases by institution.
 Institution Cases 
(n)
IRCCS Fondazione Istituto Nazionale Tumori, Milano, Italy 12
Gustave Roussy Cancer Campus, Villejuif, France 9
Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France 7
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National Cancer Center Hospital, Tokyo, Japan 7
University of Michigan, Ann Arbor, Michigan, USA 5
Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland 4
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical 
College, New York, USA
4
Università Campus Bio-Medico di Roma, Roma, Italy 3
La Timone University Hospital, Aix-Marseille Université (AMU), Marseille, 
France
3
The University of Texas MD Anderson Cancer Center, Houston, Texas 3
Leiden University Medical Center, Leiden, the Netherlands 2
S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy 2
N.N. Blokhin Russian Cancer Research, Moscow, Russian Federation 1
Northwell Cancer Institute and Cold Spring Harbor Laboratory, New York, 
USA
1
Radboud University Medical Center, Nijmegen, the Netherlands 1
Nuovo Ospedale "S.Stefano", Prato, Italy 1
TOT= 72
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 Both 39 (54%)











Stage at the time of treatment start 
(%)
• Localized/locally advanced 
(curative intent)



























IQR: interquartile range; IHC: immunohistochemistry; FISH: fluorescence in situ 
hybridization; MPS: massive parallel sequencing.
* 72 unique patients; 26 patients received more than one treatment
** 1 patient was treated with surgery and adjuvant chemotherapy and died of disease; 1 
patient was treated with neo-adjuvant chemotherapy and surgery and he it is currently 
disease free.
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Table 3. Treatment and outcome in patients treated with anthracycline-based 
regimens for localized disease.
 All Adjuvant CT Neo-adjuvant CT
CT (%) 24 16 (67%) 8 (33%)
Surgery (%)
 Post-operative RT (%)
22 (92%)
5 (23%)
16 (73%) 6 (27%)
Exclusive RT (%) 2 (8%)* - 2 (100%)
Alive and disease free > 2 years 5
CT: chemotherapy; RT: radiation therapy
* 1 patient was treated with proton therapy; 1 patient received 60 Gy (30 fractions) through 
volumetric modulated arc therapy.  
Figure 1. Intimal sarcoma patients treated with anthracycline-based regimens. 
Kaplan-Meier curves for recurrence-free survival (A) and overall survival (B) in patients 
treated for localized disease with curative intent (n=24); progression-free survival (C) and 
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Overall 42 34 19 15 12 10 6 3 3 3 3 3 3
No. pts at risk








































Overall 42 41 34 28 22 19 16 14 11 10 9 8 6
No. pts at risk
21.8  (IQR: 10.3-38.0)
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